Spots can also look very different depending on your skin tone. Some pink, red, or brown spots are more obvious on fair to ...

If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in ...

Researchers studied the relationship between age and the risk for skin cancer and oncovirus infections among patients with HIV.

One dose of the Jynneos vaccine was 58% effective against mpox infection overall and 84% in people without HIV, but only 35% ...

Tecovirimat failed to reduce clade II mpox lesions, pain or viral clearance among participants in a study of the antiviral ...

Once it reaches the skin, TB can cause a variety of lesions, most often on the legs ... in global regions with a higher prevalence of HIV or other conditions that reduce the ability of the ...

This is because IgE-mediated allergic reactions involve a chemical called histamine that causes blood vessels under the skin to dilate (widen) and release fluid into nearby tissues. There are also ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control ... immune systems or certain preexisting ...

HIV status, vaccination status, and duration of symptoms, that might be associated with clinical mpox resolution and when mpox DNA was no longer detectable in skin lesions among the study participants ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet, external medical journal.

We made a decision for one centimeter around each of the lesions because we know that very lesional skin also has a little bit of inflammatory infiltrate. We didn't try [broad application] but it ...